Astor Perkins’ Post

#FDA #Approves #Drug #to #Treat #Pain #Without #Opioid #Effects "The drug, #Journavx #by #Vertex #Pharmaceuticals, #blocks #pain #signals #to the #brain, making it #nonaddictive."

InFormed Consent introduces remote procedural consent and platform expansion to clinical research and pharmaceutical markets. Read more at https://bit.ly/3WhaNIj. #informedconsent #remoteproceduralconsent #remoteinformedconsent #CRO #clinicalresearch #readmore #learnmore #painmanagement #spine #spineprocedure #spinesurgery #plasticsurgery #orthopedicsurgery

👁️ Lupin Launches First Generic Version of AbbVie’s Eye Disorder Drug 👁️ In a significant development for ophthalmology treatments, Lupin has launched the first generic formulation of AbbVie’s drug to treat an eye disorder. This move is set to increase accessibility to crucial eye care medications, offering a more affordable option for patients. Key highlights: Lupin’s generic version aims to make treatment for eye disorders more affordable. A major step towards improving accessibility to advanced eye care solutions. Potential to impact the ophthalmology market significantly. Learn more about Lupin’s latest launch and its potential impact on the healthcare industry in this Financial Express article: Sushmita Panda Sakshi Kuchroo Sumana Sarkar Roshun Povaiah Syed Fazal Bari #Ophthalmology #EyeCare #Healthcare #Pharma #GenericDrugs #Lupin #PharmaInnovation #FinancialExpress

A molecule that activates the body's own ability to heal itself? Check out the revolutionary science at NervGen Pharma Corp. and learn more about NVG-291 by reading this Q&A between Michael Kelly, CEO, and Michael Hollan of Pharmaceutical Executive 👇 https://lnkd.in/ew4wcvvg

A new 24-month study results showcase the remarkable efficacy of Trinity Elite in lumbar spinal fusion: • 95.3% fusion success, confirmed by independent review of thin-cut CT and lack of angular and translational motion • High rates of successful lumbar arthrodesis regardless of surgical approach or risk factors • Significant improvements in pain and disability scores With more than 15 years on the market and 350,000 procedures recorded, Trinity allografts have consistently demonstrated safety and performance in aiding bone repair. This latest study reinforces Trinity Elite an efficacious alternative to autograft for musculoskeletal defects. Tissues are exclusively processed by MTF Biologics. Read the full publication at https://lnkd.in/gtk2TSr8 and learn more about Trinity Elite at https://lnkd.in/gdr5VB9T #TrinityElite #LumbarSpinalFusion #SpineSurgery #BoneHealing #MTFBiologics #Orthofix

A new 24-month study results showcase the remarkable efficacy of Trinity Elite in lumbar spinal fusion: • 95.3% fusion success, confirmed by independent review of thin-cut CT and lack of angular and translational motion • High rates of successful lumbar arthrodesis regardless of surgical approach or risk factors • Significant improvements in pain and disability scores With more than 15 years on the market and 350,000 procedures recorded, Trinity allografts have consistently demonstrated safety and performance in aiding bone repair. This latest study reinforces Trinity Elite an efficacious alternative to autograft for musculoskeletal defects. Tissues are exclusively processed by MTF Biologics. Read the full publication at https://lnkd.in/gtk2TSr8 and learn more about Trinity Elite at https://lnkd.in/gdr5VB9T #TrinityElite #LumbarSpinalFusion #SpineSurgery #BoneHealing #MTFBiologics #Orthofix

💊 𝗙𝗼𝗿𝗺𝗼𝘀𝗮, 𝗠𝗲𝗱𝘃𝗶𝘀𝗶𝘀 𝗲𝗻𝘁𝗲𝗿 𝗹𝗶𝗰𝗲𝗻𝘀𝗶𝗻𝗴 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 𝗳𝗼𝗿 𝗰𝗹𝗼𝗯𝗲𝘁𝗮𝘀𝗼𝗹 𝗽𝗿𝗼𝗽𝗶𝗼𝗻𝗮𝘁𝗲 𝗼𝗽𝗵𝘁𝗵𝗮𝗹𝗺𝗶𝗰 𝘀𝘂𝘀𝗽𝗲𝗻𝘀𝗶𝗼𝗻 𝘁𝗼 𝘁𝗿𝗲𝗮𝘁 𝗽𝗼𝘀𝘁-𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗽𝗮𝗶𝗻 ⚕️ Formosa Pharmaceuticals, based in Taiwan, has entered into an exclusive licensing agreement with Medvisis Switzerland AG for the commercialization of 𝗰𝗹𝗼𝗯𝗲𝘁𝗮𝘀𝗼𝗹 𝗽𝗿𝗼𝗽𝗶𝗼𝗻𝗮𝘁𝗲 𝗼𝗽𝗵𝘁𝗵𝗮𝗹𝗺𝗶𝗰 𝘀𝘂𝘀𝗽𝗲𝗻𝘀𝗶𝗼𝗻 (𝗔𝗣𝗣𝟭𝟯𝟬𝟬𝟳) in Switzerland and Liechtenstein.  • This treatment targets post-operative inflammation and pain following ocular surgery.   Its novel formulation allows for a simple twice-daily dosing regimen for 14 days, providing rapid and sustained relief from inflammation and pain. • Medvisis, led by experienced leaders from Novartis and GSK, has strong ties with Swissmedic. The product, FDA-approved in March 2024, was launched in the US in September 2024.  The licensing agreement includes an upfront payment, sales milestones, and additional considerations. 🥼 Ophthalmologists appreciated its convenience and safety profile. With over 100,000 cataract surgeries performed annually in Switzerland, APP13007 has strong market potential, addressing a market worth over US$ 2.1 million for single-agent corticosteroids with more complex dosing regimens. Keep track of the latest developments in clinical trials and regulatory compliance with expert-driven insights with Innovate Research. #CRO #Innovation #Pharmaceuticals #Biotechnology #PublicHealth #SME #DrugDiscovery #PharmaInnovation #ClinicalResearch #Biotech #Healthcare #SafetyEvaluation #FormosaPharmaceuticals #Medvisis #ClobetasolPropionate #OphthalmicTreatment #PostOperativeCare #CataractSurgery #EyeHealth #FDAApproved #LicensingAgreement #PharmaNews #InnovativeTreatment #PainRelief #InflammationTreatment #Ophthalmology #PharmaceuticalPartnership #SwissMed #Nanotechnology

I know some believe that I hold too bleak a view on the medical publishing industry and its negative impact on clinical research but here is a very recent research letter from JAMA that continues to show that the medical publishing industry is broken… and why broader disclosures matter. A more thorough and better structured peer review is absolutely necessary… From 2020 to 2022, over $1 billion was paid to peer reviewers of major medical journals by pharmaceutical companies and device manufacturers. The relationships of the peer reviewer are often not disclosed but have the potential to impact how clinical research is reviewed and published. Again, whether you like hearing it or not… we need to be better #orthopedicsurgery #neurosurgery #spinesurgery #interventionalspine #clinicalresearch

Knee Osteoarthritis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies Involved by DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Knee Osteoarthritis pipeline constitutes 50+ key companies continuously working towards developing 60+ Knee Osteoarthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Weekly Ophthalmic News Update – the latest news & trends you need to know: Visus Merges with Tenpoint Therapeutics, Ltd., Will Advance Brimochol Once-Daily Presbyopia Drop Candidate: https://bit.ly/4gpGHLB ACELYRIN, INC.’s Izokibep Misses Endpoints in Phase IIb/III Uveitis Trial: https://bit.ly/4gQUURl NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90) Reports Promising Preclinical Results in Restoring Vision After Optic Nerve Damage: https://bit.ly/4fv3T9V Aflibercept Biosimilar Candidate from Celltrion Inc Gains Positive CHMP Opinion: https://bit.ly/4gLNE9w ViaLase, Inc Teams up with John A. Moran Eye Center to Enhance Femto Laser Glaucoma Procedure: https://bit.ly/3ZTufN9 SIFI Files for UK Approval of Akantior Drops for Acanthamoeba Keratitis: https://bit.ly/3VTqo1v NIDEK USA Launches NP-T Preloaded Toric IOL Injector Globally: https://bit.ly/3VSlWQs Nicox Reports First Sale of Zerviate in China by Partner OcuMension: https://bit.ly/3BJoWYw Register for free on Market-Scope.com to read more ophthalmic news: https://buff.ly/3mmLOlG #Ophthalmology #Ophthalmic #News #Revenues #Cataract #Glaucoma #Retina #Refractive #Cornea #Surgical #Pharma